DAVID C PORTNOY M.D. NPI 1679529473

NPI Details

David C Portnoy, M.D. is a hematology and oncology internal medicine in Germantown, TN with 23 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. David C Portnoy, M.D. NPI is 1679529473. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

7945 WOLF RIVER BLVD
GERMANTOWN, TN
ZIP 38138-762
Phone: (901) 683-0055
Fax: (901) 685-9718

The NPI 1679529473 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, trilaciclib, 1mg (HCPCS:J1448)
• Injection, pertuzumab, 1 mg (HCPCS:J9306)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg (HCPCS:Q5117)
• Injection, durvalumab, 10 mg (HCPCS:J9173)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Liver function blood test panel (HCPCS:80076)
• Injection, rituximab-arrx, biosimilar, (riabni), 10 mg (HCPCS:Q5123)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, octreotide, depot form for intramuscular injection, 1 mg (HCPCS:J2353)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month (HCPCS:99490)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Therapy procedure using manual technique, each 15 minutes (HCPCS:97140)
• Nephelometry, test method using light (HCPCS:83883)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Unclassified drugs (HCPCS:J3490)
• Blood creatinine level (HCPCS:82565)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Folic acid level, serum (HCPCS:82746)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Magnesium level (HCPCS:83735)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Blood test, clotting time (HCPCS:85610)
• Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes (HCPCS:97110)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Phosphate level (HCPCS:84100)
• Uric acid level, blood (HCPCS:84550)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Therapy procedure using functional activities (HCPCS:97530)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Automated urinalysis test (HCPCS:81003)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Injection, mannitol, 25% in 50 ml (HCPCS:J2150)
• Training for self-care or home management, each 15 minutes (HCPCS:97535)
• Blood glucose (sugar) level (HCPCS:82947)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Red blood count, automated test (HCPCS:85045)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Flow cytometry technique for dna or cell analysis, 16 or more markers (HCPCS:88189)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Vitamin d-3 level (HCPCS:82306)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Blood test, lipids (cholesterol and triglycerides) (HCPCS:80061)
• Rheumatoid factor level (HCPCS:86431)
• Injection of drug or substance into vein (HCPCS:96374)
• Evaluation for physical therapy, typically 30 minutes (HCPCS:97162)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) (HCPCS:G0506)
• Declotting of central venous tube (HCPCS:36593)

The enumeration date for this NPI number is 5/25/2006 and was last updated on 5/2/2018.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.